Summary. Objective: The main objective of this study was to examine factors associated with utilization and costs for persons with haemophilia. Study design: Utilization data and patient characteristics were collected through medical record review of 336 patients receiving treatment for at least 90% of their haemophilia care at one of five comprehensive haemophilia treatment centres in California. Principal findings: The range of factor VIII deficiency in our sample was similar to the distribution among haemophilic patients in the Western United States; 215 (64%) had severe FVIII deficiency. The mean age in our sample was 21.4 (SD ¼ 16.2) years old and 114 (34%) were HIV-positive. In the multivariate model predicting the total cost of health care during 1995 (adjusted R 2 ¼ 0.40), total annual costs were significantly (P < 0.05) associated with being HIV-seropositive, infusing FVIII concentrate through a port vs. i.v. infusion, the number of comorbidities, moderate arthropathy (compared with no arthropathy), mild arthropathy, history of inhibitor to FVIII, and current prophylactic FVIII concentrate infusion. Conclusion: As expected, total health-care costs were correlated with comorbid medical conditions, such as HIV and sequelae of haemophilia such as arthropathy. Health policy should consider risk adjustment for the presence of complications such as arthropathy and HIV infection in the financing of haemophilia treatment to promote more equitable delivery of these services.
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Introduction
The treatment of haemophilia is a costly, lifetime commitment on the part of the provider, payer and patient. Recent cost-studies have demonstrated that over 70% of haemophilia care costs are attributable to the cost of factor VIII infusion. For instance, Globe et al. [1] reported an annual cost of $139 000 (SD $304 033.80) for haemophilia care in 1995. FVIII concentrate infusion was 72% of total costs overall, ranging from 45 (mild) to 83% (severe).
Other cost estimates from the United States range from $65 000 [2] to $92 000 [3] . European costestimates have range from 1833 in the United Kingdom (Euros) to 11 300 (Euros) for patients on prophylaxis in Italy [4] . Over the past 10 years, legislative changes concerning public funding for the treatment of haemophilia have created a need to identify characteristics associated with the utilization of health-care resources for haemophilia patients. State Title V Programs funded 19% of the haemophilia-care for patients treated at Hemophilia Diagnostic and Treatment Centers (HTCs) in California [5] . While an additional 29% were funded by Medi-Cal. From 1993 to 1994, there was a 16% increase in the proportion insured by Medi-Cal.
To address rising costs in public programmes, policy makers in California have moved Medi-Cal patients from fee-for-service to managed care providers. It is unknown what impact this may have. However, managed care providers who care for patients with the greatest burden of illness may have a disincentive to deliver services, as they may consume more resources than providers caring for patients with low haemophilia severity and few medical comorbidities. For instance, costs of treatment exceeded the revenue of contracts between payers and providers in the United Kingdom [6] . In order to assist providers and haemophilia treatment centres in assessing the adequacy of reimbursement contracts, while maintaining the provision of quality haemophilia care, research is needed to determine which factors predict greater (or less) than average costs for a specific group of beneficiaries. Disability-related costs have been shown to be lower for patients receiving FVIII prophylactically in one of six European countries after adjusting for age and the degree of arthropathy [7] . Models, which determine the association between patient characteristics and the cost of care, have not been developed in an US population.
The purpose of this study was to explore the sociodemographic and clinical characteristics associated with medical resource utilization among persons with haemophilia A. This analysis can ultimately help in assessing the potential impact of changes in benefit plans on utilization and health status in two ways. First, the estimation of utilization and costs while adjusting for patient, sociodemographic and clinical characteristics will establish a baseline against which utilization and outcomes can be compared following changes in benefits. The associations between these characteristics and utilization can be used to estimate predicted utilization. This value can be compared with actual utilization in other populations to identify trends of over-or under-utilization following a change in benefits or source of care (e.g. transition of general haemophilia care from HTCs to primary-care providers). Secondly, this information can also be used to develop risk adjustment models for more equitable reimbursement to haemophilia-care providers.
Material and methods
We conducted a retrospective chart review of health services provided to 336 patients receiving treatment for at least 90% of their haemophilia care at one of three HTCs in Southern California or one of two HTCs in Northern California, during the time period of 1 January 1995 to 31 December 1995. Data collection methods have been described in detail elsewhere [1] . Briefly, a standardized form was employed to collect patient demographics and clinical information. Data were collected through the assistance of a key staff member at each participating HTC. To protect patient confidentiality, only the centre staff member read the chart while the data abstract recorded the utilization and clinical characteristics pertinent for the data abstraction. In each case, these providers had a long-standing relationship with each patient and had been directly involved in delivery of the patient's primary and haemophilia care.
Sociodemographic characteristics
Sociodemographic characteristics including age, gender and type of insurance were collected from the outpatient medical record.
Health status
Health status was assessed by the provider on a four item scale described elsewhere [8] .
Clinical characteristics
Clinical characteristics including mode of factor concentrate (factor) administration and HIV status were abstracted from the patient chart with the assistance of the provider. The number and type of comorbid diseases, including history of central nervous system bleeds, seizure disorder, hypertension, complications of HIV and diabetes, were also collected. The severity of haemophilia was categorized by the per cent of FVIII deficiency (severe <1%, moderate 1-5%, and mild 6-50%). Severity classification for HIV was determined by CD4 count (<50, 50-100, 100-250, 250-500 and >500). The presence of arthropathy was measured on a fourpoint scale (1 ¼ none, 2 ¼ recurrent joint involvement, 3 ¼ joint involvement with some limited range of motion and some pain most of the time, 4 ¼ severe/disabling) based on information contained in the chart. As this was a retrospective analysis, X-rays and range of motion analyses were not conducted to categorize arthropathy.
Utilization. Utilization was measured for both reimbursed and non-reimbursed services, including the number of medical doctor visits (regular or extended), nurses visits, phone contacts, laboratory, radiographic and electrophysiological tests, genetic counselling, psychosocial care, surgical care, dental care, physical therapy and occupational therapy. Prescriptions for medication other than factor concentrate were categorized as haemophilia-related medication, HIV-related medications, hepatitis-related medications, and other medications. The number of prescriptions in each category was recorded. Hospital encounters were recorded as the number of emergency room visits, hospitalizations and inpatient surgical procedures performed. The length of stay and discharge diagnoses were also documented for each hospitalization.
Total cost of care. The components of the cost of care were based on the utilization of physician ambulatory visits, non-physician ambulatory visits, imaging, diagnostic, laboratory, psychosocial, hospital and pharmaceuticals during the index period using the Medicare Fee Schedule [1] . The total cost of care for an individual patient during the target period was the sum of the costs of all categories.
Analysis
Descriptive statistics. Descriptive statistics included patient, sociodemographic, health status and clinical characteristics, as well as ambulatory and hospital utilization of care, and total cost of care.
Multivariate analysis. This analysis was divided into four categories employing four separate dependent variables: ambulatory physician visits, occurrence of hospitalization, length of hospital stay and total cost of care.
Multiple regression analysis was used to build the predictive model of the cost of care for each type of utilization. A dummy variable for each treatment centre was included in each regression model as a surrogate for institutional-level factors that may have influenced the outcome variable.
The general predictive model for the cost of care can be specified as follows:
Variables from each of these categories were entered into the cost of care model. We hypothesized that lower resource use at the HTC would be associated with being young, female, having higher functional health status, mild or moderate FVIII deficiency (compared with severe FVIII deficiency), no history of arthropathy, no co-morbid diseases, no HIV, on-demand infusion, no inhibitor to FVIII, and not receiving all primary care at the HTC. We expected our HTC utilization and cost data to be highly skewed, similar to other health services research studies [9] . A skewed distribution leads to concern over the validity of the statistical inferences made when using parametric statistical methods. To adjust for the skew, we used a log-normal regression [9] . A smearing estimate method was used to retransform the log of total costs back to costs [10] .
Results

Sociodemographic, patient clinical, health-care system characteristics
The majority of our sample was abstracted from HTCs in Southern California (72.4%), with the remainder from Northern California HTCs. Nearly one-half (49.7%) of the patients received at least 50% of their primary care (non-haemophilia) from a physician not affiliated with the HTC. The mean age of this cohort was 21.4 years (SD ¼ 16.2) with 49.3% under the age of 18 years. In keeping with the X-linked cause of this disease, only a small proportion of our sample was female (1.5%) ( Table 1) . Nearly two-thirds of the patients were HIV-positive.
Multivariate model
Ambulatory utilization costs. The variability of annual cost of care for individuals with haemophilia was explained by sociodemographic characteristics, clinical comorbidities, type of health-care delivery system, and ancillary health-care needs, e.g. the use of chronic venous access devices. The degree of physician and allied health-care utilization explained 28% of the variation of costs for the year (adjusted R 2 ¼ 0.28). Two clinical variables (severity of arthropathy and the number of co-morbidities) were associated with greater ambulatory utilization costs. As expected, being an adult and receiving less than 50% of primary care at the HTC were individually associated with lower ambulatory costs during 1995.
Hospitalization. Of the 19% of patients who experienced a hospitalization during the study year, 1.2% were admitted to the ICU and 0.9% were treated in a rehabilitation unit for at least a portion of their hospital stay. Twenty-seven per cent of the hospitalizations were trauma-related, 77.8% were haemophilia-complication related, and 27.0% were HIV-related. There were 103 (30.7%) participants, who had at least one emergency room visit during 1995.
Multivariate regression of the days hospitalized per year explained 36% of the variation in the number of days of hospitalization. As expected, longer lengths of stay were associated with a greater number of co-morbidites and the presence of severe or moderate FVIII deficiency compared with the presence of mild FVIII deficiency. The relationship between being under 18 years of age, mild arthropathy, moderate arthropathy and history of inhibitor were in the hypothesized directions; however, the parameter estimates were not statistically significant. Surprisingly, HIV-positivity did not add to the hospitalization model. Neither the occurrence of a hospitalization nor the total number of days throughout the year that the patient would spend in the hospital was associated with being HIV-positive.
Total cost of health care. The model of the total costs of health care during 1995 explained the greatest amount of variance (40%) of all of our utilizationbased models ( Table 2) . As expected, a number of clinical characteristics was associated with the total cost of care. The mean estimated annual cost, from this regression model, for an adult with moderate or mild haemophilia, who has no arthropathy, no comorbidities, no inhibitor, or no HIV seropositivity, and who infuses on demand, is $18 980. The total cost of care for patients with less than 1% normal FVIII activity (severe deficiency) was 267% more than those with greater than 1% FVIII activity. Therefore, based on this model, the annual cost-estimate for an adult patient with severe FVIII deficiency but without arthropathy, other comorbidities, inhibitors, or HIV, and who infuses on demand, is $69 656. Infusion through a port or catheter raises the annual cost of care by 348% more than the cost without a chronic venous access device (P < 0.01); mild and moderate arthropathy (compared with no arthropathy) raises the annual costs by 146 and 267%, respectively, P < 0.01; a history of inhibitor to FVIII concentrate raises the annual cost of care by 172%, P < 0.01; and episodic prophylactic infusions raise the annual cost of care by 123%, P < 0.001. These were all associated with significantly higher total health-care costs. The total number of comorbidities was not significantly associated with increased total cost of care. Nor was the presence of additional disease states, such as diabetes, hypertension, complications of HIV, history of central nervous system bleed, and seizure disorders, significantly associated with increased total cost of care. Functional health status, as measured by the Hemophilia Utilization Group Study (HUGS) Functional Health Status Scale was not significantly associated with total costs. Not surprisingly, receiving less than 50% of primary care at the HTC was associated with 82% lower annual cost (P < 0.05).
Discussion
This study successfully identified the specific patient sociodemographic, clinical and health system characteristics, which are most critical to determining the total cost of care for individuals with haemophilia. A determination of the predictors of medical resource use is necessary to risk-adjust reimbursement for providers of haemophilia care to insure continued access to an appropriate range of health-care services for this vulnerable population of patients.
To compare utilization of health services among various groups of patients, investigators have recognized the importance of adjusting for functional health status or clinical characteristics, but no consensus has been reached on what measures should be used in the adjustment. Some investigators have adjusted utilization with the number of reported days of activity limitation or disability [11] , while others have used clinical characteristics to adjust utilization [12] . In one study, physician visits were adjusted for self-rated health and for the presence of chronic conditions in order to compare the insured and the uninsured [13] . Still others have used the same two measures to adjust ambulatory visits for comparison between whites and African-Americans. Risk-adjustment methods have been used to anticipate or predict patient outcomes and to compare the outcomes of assorted approaches to care [14, 15] . These methods have been used to equalize groups of patients by taking into account the pre-existing patient differences [16] . The Centres for Medicare and Medicaid Services (CMS), formally the Health Care Financing Association (HCFA), has proposed risk-adjustment of administrative data as a means of equalizing capitated payments to managed care providers across varied populations of patients [17] . According to this study, the haemophilic patients with additional clinical complications, such as arthropathy and HIV, are at greater risk for higher utilization/costs compared with those without arthropathy and HIV.
Modelling of ambulatory encounters revealed a positive association between the outcome variables (physician and allied health-care encounters) and age squared. This curvilinear relationship suggests greater utilization by younger children, decreasing to Functional health status >7 on ten-point scale, 0 (lowest functional status)-10 (highest functional status). àcompared with 1-50% normal FVIII levels, severe is less than 1% of normal FVIII levels. §compared with no arthropathy.
-Dummy variables for four of the five haemophilia treatment centres were included in the model. Each variable is compared with cost at haemophilia treatment centre 1. **less than 18 years of age.
parameter estimates from logged costs.
a minimum in early adulthood, rising once again as the patient ages. This pattern of utilization has been reported elsewhere in the health-services literature [18] . Understanding the likelihood of higher utilization during the earlier years of haemophilia care is critical in planning for the allocation of resources and risk-adjusting reimbursement. In conjunction with prophylactic treatment, intensive treatment in the early years of life might decrease sequelae later in life [19] . This information can be used to set utilization targets for disease management programmes. It can also be used in determining equitable per member per month reimbursement for providers and insurers of persons with haemophilia. Three major areas that require significant clinical consideration in the management of haemophilia are orthopaedic problems (arthropathy), infectious diseases (HIV and hepatitis) and the development of inhibitors to FVIII. Surprisingly, the presence of an inhibitor was not statistically significant in the model, although it did improve the explanatory power of the model. Although this subgroup represented a small proportion of the overall cohort, patients with inhibitors to factor concentrate increased the total costs for provision of care for patients with haemophilia, on the whole both in the cohort and in the general haemophilia population. Therefore, provision for the occurrence of this complication needs to be made when allocating resources for care in this population of patients by adjusting for the presence of inhibitors in any risk adjustment model.
The presence of HIV was significantly associated with higher outpatient costs. Therefore, the impact of HIV on the treatment and utilization of patients with haemophilia continues to hold important policy relevance. Although no new cases are expected to arise from HIV transmission via the blood supply, funding decisions must consider the increased costs associated with the care of these patients.
One component of the model, which explained the variation in the cost of total health care, was prophylactic infusion. Similar to the findings reported by Bohn et al. [7] the cost of prophylactic infusion dampens the financial savings from the reduction in hospitalizations, lost days from work or school and surgical procedures [20] [21] [22] . Future studies will need to integrate the impact of prophylaxis on quality of life and other indirect costs to completely assess the cost impact of this treatment.
Our study demonstrated that the costs of haemophilia care are predominantly driven by patient and clinical characteristics. Specifically, patients with more severe arthropathy had greater health-care costs. This is not surprising, as the presence of arthropathy increases the likelihood of repeated joint bleeding in patients with haemophilia. Also, as expected, total health-care costs were correlated with the severity of haemophilia, the presence of comorbid medical conditions, HIV, exhibiting inhibitors to FVIII concentrate and infusing factor concentrate prophylactically. Age was not a significant predictor of total health-care costs, although there was a curvilinear relationship between age and frequency of outpatient encounters. Efforts to control costs and risk adjust for reimbursement need to address these parameters.
Risk adjustment, the simplest and most basic approach for equitable reimbursement, is accomplished through retrospective analysis of administrative databases. However, retrospective chart review, as conducted in this study, is a time-consuming and costly process. An alternative is to use other information which can be provided by the provider without a comprehensive chart review. The HUGS Functional Status Scale is one such potential tool [8] . This scale was significantly associated with the resource models. When the clinical characteristics were removed from the model of the costs of total health-care resources used, higher functional status as measured by this scale was associated with lower resource use. While the HUGS Functional Status Scale alone did not explain as much variation in resource use as the full model, this scale could be used as a surrogate for chart reviews in the risk adjustment process.
Up to two-thirds of managed care contracts are placing physicians at financial risk for the care of patients [23] . These arrangements have incentivized physicians to focus on utilization patterns in their practice and short-term outcomes with the potential cost of diminished health status in the long-term. This probably explains the lower annual cost of care provided to haemophiliacs outside of the HTC system. The long-term financial and personal consequences of this health-care rationing cannot be determined by this study but are probably reflective of decreased use of replacement therapy, decreased use of early joint replacement surgery and decreased recommendation of prophylactic regimens. The data from our study may serve as a framework from which to anticipate future medical resource needs and establish equitable financing for the provision of care through risk-adjustment arrangements that reflect the increased costs of arthropathy, HIV and other sequelae of haemophilia and the importance of a long-term perspective in the management of health care for these patients. The long-term impact, such as the development of arthropathy and other complications of poorly managed care, must be included in financing decisions for the treatment of individuals with chronic, high-cost diseases such as haemophilia. It is equally important to establish mechanisms to minimize the impact of adverse selection on those providing care to patients with both long-term and costly diseases. Understanding of the predictors of utilization and cost can be used to assist in the formulation of risk-contracting systems as a first step in creating efficient and equitable payment to Medicaid and managed care providers, while maintaining necessary and sufficient care for vulnerable groups of patients, such as those with haemophilia. The authors would like to thank Judith R. Baker, M.H.S.A. and the MTC's for providing demographics for the hemophilia population.
